Status:
COMPLETED
Clinical Efficacy of Qingxin Zishen Decoction in Treating Menopausal Syndrome and Neuroendocrine Mechanism of Regulating KNDy Neurons
Lead Sponsor:
Yun Chen
Conditions:
Menopause
Eligibility:
FEMALE
41-55 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to determine the effects of estrogen (Fenmotong) and Qingxin Zishen Decoction on the levels of kisspeptin, NKB, and dynorphin expressed in human KNDy neurons Between...
Eligibility Criteria
Inclusion
- Women aged 41\~55;
- KIM score≥ 15 points;
- The number of hot flashes and sweating≥ 3 times/day;
- Menopause time≥ 6 months;
- FSH\>30mIU/ml,E2\<30ng/L;
- Informed consent, voluntary testing.
Exclusion
- Unexplained vaginal bleeding;
- Sex hormone-related malignant tumors cannot be excluded;
- premature ovarian failure, or endometriosis, or hysterectomy, or bilateral adnexectomy;
- Combined with primary liver and kidney dysfunction, cardiovascular and cerebrovascular diseases, blood system diseases and other serious diseases that affect their survival;
- Exposure to sex hormone-related drugs within 3 months;
- Patients with mental abnormalities, or those with a history of alcohol or drug abuse;
- Those who have allergic reactions to the study drug;
- Those who are participating in other drug clinical researchers.
Key Trial Info
Start Date :
April 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06132620
Start Date
April 1 2017
End Date
June 30 2018
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yuxin Zhou
Nanjing, 南京, China